ArticleTherapeutic advances in psychopharmacology2011
Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor.
Article in Therapeutic advances in psychopharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature.Clinical pharmacokinetics · 2017Pooled it
- Vilazodone Hydrochloride-Loaded Nanostructured Lipid Carrier In Situ Gel for Intranasal Nose-to-Brain Antidepressant Delivery.AAPS PharmSciTech · 2026Article
- Long-term neuronal and neurocognitive consequences in offspring after prenatal exposure to a novel antidepressant, vilazodone: Role of BDNF/Bax-Bcl-2/AChE mediated pathways.Psychopharmacology · 2026Article
- Did Serendipity Contribute to the Discovery of New Antidepressant Drugs? Historical Analysis Using Operational Criteria.Alpha psychiatry · 2025Article
- Navigating the depths: A comprehensive narrative review on depression in people with epilepsy.Heliyon · 2025Review
- An Open-Label Rater-Blinded Randomized Trial of Vilazodone versus Escitalopram in Major Depression.Indian journal of psychological medicine · 2023Article
- Synergism between Extracts ofNutrients · 2022Article
- The clinical utility of newer antidepressant agents: Understanding the role in management of MDD.The mental health clinician · 2022Article
- Vilazodone for Major Depression in Adults: Pharmacological Profile and an Updated Review for Clinical Practice.Neuropsychiatric disease and treatment · 2022Review
- The Cardiovascular Effects of Newer Antidepressants in Older Adults and Those With or At High Risk for Cardiovascular Diseases.CNS drugs · 2020Review
- B(CACS catalysis · 2020Article
- The Potential Role of the Pharmacist in Supporting Patients with Depression - A Literature-Based Point of View.Integrated pharmacy research & practice · 2020Review
- The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2018Article
- Neurochemical and behavioural effects of hypidone hydrochloride (YL-0919): a novel combined selective 5-HT reuptake inhibitor and partial 5-HTBritish journal of pharmacology · 2017Article
- Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: A narrative literature review.The mental health clinician · 2016Article
- Review
- Major depressive disorder: mechanism-based prescribing for personalized medicine.Neuropsychiatric disease and treatment · 2015Review
- Antidepressant efficacy and side-effect burden: a quick guide for clinicians.Drugs in context · 2015Review
- Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy.Core evidence · 2015Review
- Psychopharmacological Practice: The DSM Versus The Brain.Mens sana monographs · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVilazodone is the latest US Food and Drug Administration approved antidepressant agent available in the USA. Its putative mechanism of antidepressant action enhances the release of serotonin across the brain's serotonergic pathways specifically by inhibiting the serotonin transporter, similar to a selective serotonin reuptake inhibitor (SSRI), and simultaneously stimulating serotonin-1a receptors via partial agonism, similar to the anxiolytic bus-pirone. This combined activity in the single vilazodone agent has been termed by the authors as being a serotonin partial agonist and reuptake inhibitor or (SPARI).
methodsA MEDLINE and Internet search was conducted and the resultant preclinical and clinical evidence was reviewed. The authors attempt to review laboratory data, animal model data and human trial data to develop a translational theory on the mechanism of antidepressant action of this agent and also its adverse effect potential.
resultsRandomized, controlled empirical data for vilazodone have gained it approval for treating major depressive disorder. It combines two well known pharmacodynamic mechanisms of serotonergic action into a novel agent. Although no head-to-head studies against other antidepressants have been published, the efficacy data for vilazodone appear comparable to other known antidepressants, with similar gastrointestinal side effects to SSRI or serotonin norepinephrine reuptake inhibitor (SNRI) antidepressants, but possibly with a lower incidence of sexual side effects and weight gain. DISCUSSION: Vilazodone will lend itself to the current armamentarium in the treatment of major depressive disorder and may hold promise for patients who cannot tolerate other antide-pressants. Its unique SPARI mechanism of action could also be efficacious for patients who do not respond to SSRI or SNRI antidepressant monotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.